|
시장보고서
상품코드
1671156
세계의 급성 림프성/림프모구성 백혈병 치료제 시장 규모, 점유율, 동향, 업계 분석 : 제품별, 용도별, 성별, 최종 용도별, 지역별 - 시장 예측(2025-2034년)Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Product, Application, Gender, End Use, and Region - Market Forecast, 2025-2034 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 조사에 따르면, 급성 림프성/림프모구성 백혈병 치료제 시장 규모는 2034년까지 69억 7,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
급성 림프성/림프모구성 백혈병(ALL) 치료제 시장의 성장은 이 질환의 유병률 증가, 치료 옵션의 발전, 조기 진단에 대한 인식 증가 등 여러 가지 요인에 기인합니다. 면역요법, 특히 키메라 항원 수용체(CAR) T 세포 치료의 부상은 재발성 또는 불응성 ALL 환자에게 새로운 희망을 가져다 주었으며, 표적 치료는 필라델피아 염색체 양성 ALL과 같은 유전적으로 정의된 아형에 대한 치료 결과를 개선하고 있습니다.
또한, 유전자 및 분자 프로파일링에 기반하여 치료 동향을 조정하는 정밀의료로의 전환이 이 시장의 중요한 트렌드입니다. 급성 림프성/림프모구성 백혈병 치료제의 시장 기회는 의료 접근성이 개선되고 효능을 높이기 위한 병용요법에 대한 지속적인 연구와 함께 의료 접근성이 개선됨에 따라 치료 접근성이 낮은 지역에서도 생겨나고 있습니다.
급성 림프성/림프모구성 백혈병 치료제 시장 : 분석 개요
제품별로는 화학요법 분야가 급성 림프성/림프모구성 백혈병 치료제 시장 매출에서 가장 큰 비중을 차지하고 있습니다. 화학요법은 ALL의 표준치료로 여겨지고 있습니다. 그러나 표적 치료제 분야는 티로신키나아제 억제제, CAR T 세포 치료제 등의 기술 혁신에 힘입어 가장 빠르게 성장하고 있는 분야입니다.
전구 B세포성 ALL은 높은 유병률로 인해 용도별로는 전구 B세포성 ALL이 지배적인 부문입니다. 반면, 필라델피아 염색체 양성 ALL 부문은 표적 치료제 사용 증가에 힘입어 가장 높은 성장세를 보이고 있습니다.
성별로는 남성이 ALL 진단을 받는 빈도가 높기 때문에 남성 부문의 시장 점유율이 높지만, 여성 부문은 조기 진단의 증가와 치료 성과의 개선으로 높은 성장세를 보이고 있습니다.
최종사용자별로는 병원 및 클리닉이 다양한 치료법을 제공함에 따라 급성 림프성/림프모구성 백혈병 치료제 시장 점유율을 독식하고 있습니다. 그러나 면역요법, 줄기세포 이식 등 고도의 종양학 치료에 특화되어 있어 암 치료 센터가 가장 빠르게 성장하고 있습니다.
북미는 높은 의료 인프라와 높은 치료 도입률로 세계 시장을 독점하고 있지만, 아시아태평양은 의료 접근성 확대와 첨단 치료에 대한 수요 증가로 인해 가장 높은 성장세를 보이고 있습니다.
목차
제1장 소개
제2장 주요 요약
제3장 분석 방법
제4장 급성 림프성/림프모구성 백혈병 치료제 시장 인사이트
- 시장 현황
- 급성 림프성/림프모구성 백혈병 치료제 시장 역학
- 성장 촉진요인과 기회
- 급성 림프성/림프모구성 백혈병의 이점에 관한 인식 향상
- 세계 요리나 퓨전 요리의 인기가 상승으로 급성
- 성장 억제요인과 과제
- 제품의 높은 한계 가격
- 성장 촉진요인과 기회
- PESTLE 분석
- 급성 림프성/림프모구성 백혈병 치료제 시장 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 급성 림프성/림프모구성 백혈병 치료제 시장 : 용도별
- 주요 분석 결과
- 소개
- 필라델피아 염색체
- 전구 B세포 ALL
- T세포성 ALL
제6장 세계의 급성 림프성/림프모구성 백혈병 치료제 시장 : 제품별
- 주요 분석 결과
- 소개
- 화학요법
- 표적요법
- 방사선 치료
- 줄기세포 이식
제7장 세계의 급성 림프성/림프모구성 백혈병 치료제 시장 : 성별
- 주요 분석 결과
- 소개
- 남성용
- 여성용
제8장 세계의 급성 림프성/림프모구성 백혈병 치료제 시장 : 최종 용도별
- 주요 분석 결과
- 소개
- 병원·클리닉
- 암 치료 센터
- 연구·학술기관
제9장 세계의 급성 림프성/림프모구성 백혈병 치료제 시장 : 지역별
- 주요 분석 결과
- 소개
- 급성 림프성/림프모구성 백혈병 치료제 시장 평가 : 지역별(2020-2034년)
- 북미
- 북미 : 용도별(2020-2034년)
- 북미 : 제품별(2020-2034년)
- 북미 : 성별(2020-2034년)
- 북미 : 최종 용도별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 용도별(2020-2034년)
- 유럽 : 제품별(2020-2034년)
- 유럽 : 성별(2020-2034년)
- 유럽 : 최종 용도별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 용도별(2020-2034년)
- 아시아태평양 : 제품별(2020-2034년)
- 아시아태평양 : 성별(2020-2034년)
- 아시아태평양 : 최종 용도별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 용도별(2020-2034년)
- 중동 및 아프리카 : 제품별(2020-2034년)
- 중동 및 아프리카 : 성별(2020-2034년)
- 중동 및 아프리카 : 최종 용도별(2020-2034년)
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 용도별(2020-2034년)
- 라틴아메리카 : 제품별(2020-2034년)
- 라틴아메리카 : 성별(2020-2034년)
- 라틴아메리카 : 최종 용도별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제11장 기업 개요
- Amgen Inc.
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Kite Pharma(a subsidiary of Gilead Sciences)
- Bristol Myers Squibb
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson(via Janssen Pharmaceuticals)
- Sanofi
- AbbVie Inc.
- Servier
- Spectrum Pharmaceuticals
- Bluebird Bio
- Celgene(now part of Bristol Myers Squibb)
- Jazz Pharmaceuticals
The acute lymphocytic/lymphoblastic leukemia therapeutics market size is expected to reach USD 6.97 billion by 2034, according to a new study by Polaris Market Research. The report "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Product (Chemotherapy, Targeted Therapy, Radiation Therapy, and Stem Cell Transplantation), Application, Gender, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market growth is driven by several factors such as the increasing prevalence of the disease, advancements in treatment options, and growing awareness about early diagnosis. The rise of immunotherapies, particularly chimeric antigen receptor (CAR) T-cell therapies, offers new hope for patients suffering from relapsed or refractory ALL, while targeted therapies are improving outcomes for genetically defined subtypes such as Philadelphia chromosome-positive ALL.
Additionally, the shift toward precision medicine, where treatments are tailored based on genetic and molecular profiling, is a key trend in the market. Acute lymphocytic/lymphoblastic leukemia therapeutics market opportunities are also emerging in underserved regions as healthcare access improves, alongside ongoing research into combination therapies to enhance effectiveness.
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Report Highlights
Based on product, the chemotherapy segment holds the largest share of the acute lymphocytic/lymphoblastic leukemia therapeutics market revenue. Chemotherapy is considered a standard treatment for ALL. However, the targeted therapy segment is the fastest-growing segment, driven by innovations such as tyrosine kinase inhibitors and CAR T-cell therapies.
Precursor B-cell ALL is the dominant segment, based on application, due to its high prevalence. On the other side, the Philadelphia chromosome-positive ALL segment is experiencing the highest growth, fueled by the increased use of targeted therapies.
The male segment, based on gender, holds a larger market share, as males are more frequently diagnosed with ALL, while the female segment is showing a higher growth, with increasing early diagnosis and improved treatment outcomes.
In terms of end use, the hospitals and clinics segment dominate the acute lymphocytic/lymphoblastic leukemia therapeutics market share, as it offers a broad range of treatments. However, cancer care centers are the fastest growing due to their specialized focus on advanced oncology therapies such as immunotherapies and stem cell transplants.
North America dominates the global market due to advanced healthcare infrastructure and high treatment adoption rates, while Asia Pacific is the highest growing, driven by expanding healthcare access and rising demand for advanced therapies.
Polaris Market Research has segmented the acute lymphocytic/lymphoblastic leukemia therapeutics market report on the basis of product, application, gender, end use, and region:
By Product Outlook (Revenue - USD Billion, 2020-2034)
- Chemotherapy
- Targeted Therapy
- Radiation Therapy
- Stem Cell Transplantation
By Application Outlook (Revenue - USD Billion, 2020-2034)
- Philadelphia Chromosome
- Precursor B-cell ALL
- T-cell ALL
By Gender Outlook (Revenue - USD Billion, 2020-2034)
- Male
- Female
By End Use Outlook (Revenue - USD Billion, 2020-2034)
- Hospitals & Clinics
- Cancer Care Centers
- Research & Academic Institutes
By Regional Outlook (Revenue - USD Billion, 2020-2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Insights
- 4.1. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Market Snapshot
- 4.2. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increased awareness of the benefits of Acute Lymphocytic/Lymphoblastic Leukemia
- 4.2.1.2. Rising popularity of global and fusion cuisines Is propelling the Acute
- 4.2.2. Restraints and Challenges
- 4.2.2.1. The high marginal price of the product
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 5.3. Philadelphia Chromosome
- 5.3.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Philadelphia Chromosome, by Region, 2020-2034 (USD Billion)
- 5.4. Precursor B-cell ALL
- 5.4.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Precursor B-cell ALL, by Region, 2020-2034 (USD Billion)
- 5.5. T-cell ALL
- 5.5.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by T-cell ALL, by Region, 2020-2034 (USD Billion)
6. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 6.3. Chemotherapy
- 6.3.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
- 6.4. Targeted Therapy
- 6.4.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
- 6.5. Radiation Therapy
- 6.5.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Radiation Therapy, by Region, 2020-2034 (USD Billion)
- 6.6. Stem Cell Transplantation
- 6.6.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Stem Cell Transplantation, by Region, 2020-2034 (USD Billion)
7. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 7.3. Male
- 7.3.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Male, by Region, 2020-2034 (USD Billion)
- 7.4. Female
- 7.4.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Female, by Region, 2020-2034 (USD Billion)
8. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 8.3. Hospitals & Clinics
- 8.3.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Hospitals & Clinics, by Region, 2020-2034 (USD Billion)
- 8.4. Cancer Care Centers
- 8.4.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Cancer Care Centers, by Region, 2020-2034 (USD Billion)
- 8.5. Research & Academic Institutes
- 8.5.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Research & Academic Institutes, by Region, 2020-2034 (USD Billion)
9. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
- 9.3. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - North America
- 9.3.1. North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.3.2. North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.3.3. North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.3.4. North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.3.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - US
- 9.3.5.1. US: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.3.5.2. US: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.3.5.3. US: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.3.5.4. US: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.3.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Canada
- 9.3.6.1. Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.3.6.2. Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.3.6.3. Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.3.6.4. Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.4. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Europe
- 9.4.1. Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.4.2. Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.3. Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.4.4. Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.4.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - UK
- 9.4.5.1. UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.4.5.2. UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.5.3. UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.4.5.4. UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.4.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - France
- 9.4.6.1. France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.4.6.2. France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.6.3. France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.4.6.4. France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.4.7. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Germany
- 9.4.7.1. Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.4.7.2. Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.7.3. Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.4.7.4. Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.4.8. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Italy
- 9.4.8.1. Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.4.8.2. Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.8.3. Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.4.8.4. Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.4.9. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Spain
- 9.4.9.1. Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.4.9.2. Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.9.3. Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.4.9.4. Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.4.10. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Netherlands
- 9.4.10.1. Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.4.10.2. Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.10.3. Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.4.10.4. Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.4.11. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Russia
- 9.4.11.1. Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.4.11.2. Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.11.3. Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.4.11.4. Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.4.12. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.4.12.2. Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.12.3. Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.4.12.4. Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Asia Pacific
- 9.5.1. Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.5.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - China
- 9.5.5.1. China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.5.5.2. China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.5.3. China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.5.5.4. China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.5.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - India
- 9.5.6.1. India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.5.6.2. India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.6.3. India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.5.6.4. India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.5.7. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Malaysia
- 9.5.7.1. Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.5.7.2. Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.7.3. Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.5.7.4. Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.5.8. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Japan
- 9.5.8.1. Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.5.8.2. Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.8.3. Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.5.8.4. Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.5.9. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Indonesia
- 9.5.9.1. Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.5.9.2. Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.9.3. Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.5.9.4. Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.5.10. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - South Korea
- 9.5.10.1. South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.5.10.2. South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.10.3. South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.5.10.4. South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.5.11. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Australia
- 9.5.11.1. Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.5.11.2. Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.11.3. Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.5.11.4. Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.5.12. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.5.12.2. Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.12.3. Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.5.12.4. Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.6.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.6.5.2. Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.5.3. Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.6.5.4. Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.6.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - UAE
- 9.6.6.1. UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.6.6.2. UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.6.3. UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.6.6.4. UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.6.7. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Israel
- 9.6.7.1. Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.6.7.2. Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.7.3. Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.6.7.4. Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.6.8. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - South Africa
- 9.6.8.1. South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.6.8.2. South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.8.3. South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.6.8.4. South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.6.9. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.6.9.2. Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.9.3. Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.6.9.4. Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.7. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Latin America
- 9.7.1. Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.7.2. Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.7.3. Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.7.4. Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.7.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Mexico
- 9.7.5.1. Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.7.5.2. Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.7.5.3. Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.7.5.4. Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.7.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Brazil
- 9.7.6.1. Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.7.6.2. Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.7.6.3. Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.7.6.4. Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.7.7. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Argentina
- 9.7.7.1. Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.7.7.2. Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.7.7.3. Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.7.7.4. Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
- 9.7.8. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
- 9.7.8.2. Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.7.8.3. Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
- 9.7.8.4. Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Amgen Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Novartis AG
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Pfizer Inc.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Takeda Pharmaceutical Company Limited
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Kite Pharma (a subsidiary of Gilead Sciences)
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Bristol Myers Squibb
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. F. Hoffmann-La Roche Ltd
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Johnson & Johnson (via Janssen Pharmaceuticals)
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Sanofi
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. AbbVie Inc.
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Servier
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Spectrum Pharmaceuticals
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
- 11.13. Bluebird Bio
- 11.13.1. Company Overview
- 11.13.2. Financial Performance
- 11.13.3. Product Benchmarking
- 11.13.4. Recent Development
- 11.14. Celgene (now part of Bristol Myers Squibb)
- 11.14.1. Company Overview
- 11.14.2. Financial Performance
- 11.14.3. Product Benchmarking
- 11.14.4. Recent Development
- 11.15. Jazz Pharmaceuticals
- 11.15.1. Company Overview
- 11.15.2. Financial Performance
- 11.15.3. Product Benchmarking
- 11.15.4. Recent Development
비교리스트